These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15170021)

  • 1. Breathlessness during exercise in COPD: how do the drugs work?
    Calverley PM
    Thorax; 2004 Jun; 59(6):455-7. PubMed ID: 15170021
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dyspnea and quality of life in chronic obstructive pulmonary disease].
    Sanjuás C
    Arch Bronconeumol; 2002 Oct; 38(10):485-8. PubMed ID: 12372199
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiotropium versus salmeterol in COPD.
    Oba Y
    N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714654
    [No Abstract]   [Full Text] [Related]  

  • 5. Tiotropium versus salmeterol in COPD.
    Lloret-Linares C; Bergmann JF
    N Engl J Med; 2011 Jun; 364(26):2552-3; author reply 2553-4. PubMed ID: 21714656
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD.
    Man WD; Mustfa N; Nikoletou D; Kaul S; Hart N; Rafferty GF; Donaldson N; Polkey MI; Moxham J
    Thorax; 2004 Jun; 59(6):471-6. PubMed ID: 15170026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiotropium versus salmeterol in COPD.
    Schembri S
    N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714655
    [No Abstract]   [Full Text] [Related]  

  • 8. Avoiding mistakes in calculating the number needed to treat in severe COPD.
    Aaron SD
    Am J Respir Crit Care Med; 2007 Jun; 175(12):1347; author reply 1347-8. PubMed ID: 17545461
    [No Abstract]   [Full Text] [Related]  

  • 9. Do we need three players in COPD treatment?
    Maestrelli P; Mason P; Costa F; Paggiaro P
    Respiration; 2013; 86(4):275-6. PubMed ID: 23988429
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
    Guenette JA; Webb KA; O'Donnell DE
    Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?
    Gillissen A
    Am J Respir Crit Care Med; 2008 Jul; 178(1):105; author reply 106-7. PubMed ID: 18565963
    [No Abstract]   [Full Text] [Related]  

  • 12. Tiotropium versus salmeterol in COPD.
    Restrick L; Stern M; Baxter N
    N Engl J Med; 2011 Jun; 364(26):2552; author reply 2553-4. PubMed ID: 21714657
    [No Abstract]   [Full Text] [Related]  

  • 13. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P
    MMW Fortschr Med; 2003 Jun; 145(24):20. PubMed ID: 12866294
    [No Abstract]   [Full Text] [Related]  

  • 14. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest.
    Boni E; Corda L; Franchini D; Chiroli P; Damiani GP; Pini L; Grassi V; Tantucci C
    Thorax; 2002 Jun; 57(6):528-32. PubMed ID: 12037229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms.
    van Noord JA; Aumann JL; Janssens E; Smeets JJ; Zaagsma J; Mueller A; Cornelissen PJ
    Respir Med; 2010 Jul; 104(7):995-1004. PubMed ID: 20303247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? No.
    Aaron SD
    Can Fam Physician; 2007 Sep; 53(9):1429-30, 1432. PubMed ID: 17872866
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy of bronchodilators: searching for objective criteria].
    Aguilaniu B
    Rev Pneumol Clin; 2003 Apr; 59(2 Pt 2):S11-5. PubMed ID: 12966780
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenetics of COPD: a role for the β2-adrenergic receptor gene?
    Jensen CS; Dahl M
    Lancet Respir Med; 2014 Jan; 2(1):3-4. PubMed ID: 24461881
    [No Abstract]   [Full Text] [Related]  

  • 19. Responsiveness of continuous ratings of dyspnea during exercise in patients with COPD.
    Mahler DA; Fierro-Carrion G; Mejia-Alfaro R; Ward J; Baird JC
    Med Sci Sports Exerc; 2005 Apr; 37(4):529-35. PubMed ID: 15809548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
    Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
    Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.